Clinical trials: Cancer, Carcinoma
Invasive Ductal Carcinoma, Invasive Lobular Carcinoma
Intraoperative Imaging of Breast Cancer With Indocyanine Green
According to the World Health Organization, breast cancer is the most common cancer in women, and is responsible for 686,000 new cases every year. The WHO also posit that nearly 420,000 women perished from the disease in 2002.
- Conditions
- Invasive Ductal Carcinoma, Invasive Lobular Carcinoma, Ductal Carcinoma
- Trial name
- ICG (NCT01796041)
- Testing
- Indocyanine Green
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Basal Cell Carcinoma of Skin, Cutaneous Squamous Cell Carcinoma (CSCC)
Impact of Preoperative High-Frequency Ultrasound Cutaneous Lesion Extent Assessment on Excision Margin Positivity in Head and Neck Skin Cancer, and the Relationship Between Preoperative Assessment Methods, Inadequate Excision Margins, and Tumor Recurrence
Non-melanoma skin cancers (NMSC), particularly basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), are the most common malignancies in Caucasians, with the majority of tumors located in the head and neck due…
- Conditions
- Basal Cell Carcinoma of Skin, Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Squamous Cell Carcinoma in Situ (CSCCis), Cutaneous Squamous Cell Carcinoma of the Head and Neck
- Trial name
- HFUS-CLEAR (NCT07361666)
- Testing
- High-Frequency Ultrasound, Dermoscopy
- Where
- Poland
- Volunteers
- 400 people
- Sponsor
- Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji
Cirrhosis of Liver
Gadoxetic Acid-MRI Versus Ultrasonography for the Surveillance of Hepatocellular Carcinoma in High-risk Patients
Current practice guidelines recommend surveillance for hepatocellular carcinoma (HCC) in liver cirrhosis patients with ultrasonography (USG) every 6 months.
- Trial name
- PRIUS (NCT01446666)
- Where
- South Korea
- Volunteers
- 423 people
- Sponsor
- Asan Medical Center
Esophageal Cancer
A Prospective Study of Tumor-specific Tpex in Negative Lymph Nodes for Predicting Pathological Complete Response to Neoadjuvant PD 1 Therapy in Esophageal Cancer
The goal of this observational study is to to determine whether patients with a high proportion of precursor exhausted T cells (Tpex) in negative tumor draining lymph nodes have higher pCR.
- Trial name
- NCT07573397
- Volunteers
- 88 people
- Sponsor
- Fudan University
Breast Cancer
Sulindac in Preventing Breast Cancer in Women at High Risk for Breast Cancer
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of sulindac may prevent breast cancer.
- Trial name
- NCT00245024
- Testing
- sulindac, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer
National Comprehensive Cancer Network (NCCN) Decision Support Tool for Patients With NSCLC
This study involves the evaluation of a decision support tool, based on the patient version of the NCCN guidelines, for the non-small cell lung cancer patient population.
- Trial name
- NCT03982459
- Testing
- Decision support tool
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- University of California, San Francisco
Thyroid Carcinoma, Surgery
Thyroid Cancer and Central Lymph Node Metastases Detection Using Bevacizumab-IRDye800CW
Background: Papillary thyroid cancer (PTC) patients often develop central lymph node metastases (CLNM), which pose a high risk of disease recurrence.
- Trial name
- TARGET-beva (NCT06095362)
- Testing
- Bevacizumab-IRDye800CW
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- University Medical Center Groningen
Colorectal Cancer Metastatic
Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer
The effectiveness and safety of TheraSphere will be evaluated in patients with colorectal cancer with metastases in the liver, who are scheduled to receive second line chemotherapy.
- Trial name
- EPOCH (NCT01483027)
- Testing
- TheraSphere
- Where
- 131 sites in United States, Austria and 11 more
- Volunteers
- 428 people
- Sponsor
- Boston Scientific Corporation
Ovarian Cancer
IM-862 in Treating Patients With Recurrent Ovarian Cancer
RATIONALE: IM-862 may stop the growth of ovarian cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of IM-862 in treating patients who have recurrent ovarian cancer after treatment with…
- Trial name
- NCT00003773
- Testing
- oglufanide disodium
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of Southern California
Breast Cancer
Radiation Therapy in Treating Women With Invasive Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy in different ways may kill more tumor cells.
- Trial name
- NCT00301041
- Testing
- laboratory biomarker analysis, adjuvant therapy, radiation therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
Solid Tumor, Advanced Solid Tumor
A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)
The implementation of liquid biopsy in clinical practice has been favored by the rapid development of genome sequencing techniques designed to analyze mutations in ctDNA.
- Conditions
- Solid Tumor, Advanced Solid Tumor, Locally Advanced Solid Tumor, Colon Rectal Cancer
- Trial name
- POPCORN (NCT06028724)
- Where
- Italy
- Volunteers
- 782 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Advanced Gastric Cancer
Efficacy and Safety of Everolimus (RAD001) in Patients With Advanced Gastric Cancer
The purpose of this study is to assess the efficacy and safety of everolimus 10mg daily in patients with advanced gastric carcinoma (inoperable, recurrent or metastatic gastric cancer) whose cancer has progressed despite prior…
- Trial name
- NCT00519324
- Testing
- Everolimus
- Where
- 8 sites in Japan
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
Hepatocellular Carcinoma
A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation
The goal of this clinical trial is to evaluate the efficacy and safety of camrelizumab plus apatinib as adjuvant therapy for patients with hepatocellular carcinoma at high risk of recurrence after radical resection or ablation.
- Trial name
- NCT06546280
- Testing
- Camrelizumab, Apatinib
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Zhujiang Hospital
Head and Neck Cancers- Squamous Cell, Head and Neck Cancer
Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
The goal of this clinical trial is to assess the safety and tolerability of a virus replicon particle (VRP) encapsulated saRNA encoding IL-12 when injected into in head and neck cancer patients.
- Conditions
- Head and Neck Cancers- Squamous Cell, Head and Neck Cancer, Solid Tumors, HNSCC
- Trial name
- NCT06736379
- Testing
- VRP-encapsulated saRNA encoding IL-12 (1 x 10^9 viral particles per injection), Pembrolizumab (KEYTRUDA®), VRP-encapsulated saRNA encoding IL-12 (3 x 10^8 viral particles per injection)
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- VLP Therapeutics
Lung Cancer
Temozolomide in Patients With Progressive or Recurrent Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effect of temozolomide in patients with progressive or recurrent stage…
- Trial name
- NCT00003062
- Testing
- temozolomide
- Where
- 5 sites in Italy, Netherlands and 3 more
- Volunteers
- 70 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Hepatocellular Carcinoma
A Study to Evaluate the Safety, Tolerability and Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma and Impaired Liver Function
This is an prospective, interventional, non-randomized multicenter phase II study to evaluate the safety, tolerability and efficacy of Cabozantinib as a second-line therapy (after one prior systemic therapy) in patients with…
- Trial name
- CaboCHILD (NCT04454762)
- Testing
- Cabozantinib
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Johannes Gutenberg University Mainz
Kidney Cancer
Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer
RATIONALE: Lenalidomide may stop the growth of kidney cancer by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well lenalidomide works in treating patients with advanced or unresectable kidney…
- Trial name
- NCT00403169
- Testing
- lenalidomide
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- The Cleveland Clinic
Urothelial Carcinoma (UC)
A Patient-Directed Mobile Tool to Streamline the QoL Assessment and Monitoring in Urothelial Carcinoma
The goal of this observational study is to select contents and tools for the future development of a web app aiming to support patients' navigation for empowering decision-making through a higher awareness of urothelial carcinoma…
- Trial name
- Urolife (NCT06982794)
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- IRCCS San Raffaele
Stage IIIA Non-small Cell Lung Cancer
Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer Patients
This is a single arm, single center phase II study of adjuvant pembrolizumab in N2 positive non-small cell lung cancer (NSCLC) patients treated with neoadjuvant concurrent chemoradiotherapy followed by curative resection.
- Trial name
- NCT03053856
- Testing
- Pembrolizumab, Curative resection, Neoadjuvant concurrent chemoradiotherapy
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- Samsung Medical Center
Urothelial Bladder Cancer, Gastric Adenocarcinoma
Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab
Treatment will consist of a PARP inhibitor (niraparib) monotherapy priming period (cycle 0; 21 days); an anti-PD-1 antibody (Dostarlimab ; TSR-042) will then be added from C1D1 every 21 days in combination for the first 4 cycles…
- Conditions
- Urothelial Bladder Cancer, Gastric Adenocarcinoma, Gastro-oesophageal Adenocarcinoma, Head and Neck Cancer
- Trial name
- NIRADO (NCT04779151)
- Testing
- Dostarlimab, Niraparib
- Where
- France
- Volunteers
- 51 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.